The CELF2 antibody is a research tool used to detect and study the CELF2 protein, a member of the CUGBP Elav-like family (CELF) of RNA-binding proteins. CELF2. also known as BRUNOL3 or NAPOR, plays critical roles in post-transcriptional gene regulation, including mRNA splicing, stability, transport, and translation. It is widely expressed in tissues, with notable roles in neuronal development, muscle function, and immune regulation. Dysregulation of CELF2 has been implicated in neurological disorders, myotonic dystrophy, and cancers, where it may act as either a tumor suppressor or promoter depending on context.
CELF2 antibodies are essential for investigating its expression patterns, localization, and interactions in cellular and disease models. They are commonly used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Commercial CELF2 antibodies are typically raised against specific epitopes, such as N-terminal or C-terminal regions, and validated for specificity using knockout controls or siRNA-mediated protein depletion. However, challenges remain due to potential cross-reactivity with other CELF family members (e.g., CELF1. CELF3-6) or isoforms generated by alternative splicing. Researchers must carefully validate these antibodies for each application. Recent studies leveraging CELF2 antibodies have uncovered its involvement in alternative splicing networks in brain development and cancer metastasis, highlighting its therapeutic and diagnostic potential.